Izotropic Canada Stock Price, News & Analysis

Izotropic Corporation (OTCQB: IZOZF) announced placement in an editorial by NetworkNewsWire on October 24, 2025 highlighting AI-driven imaging firms targeting the breast cancer market.

The company is noted for its IzoView Breast CT Imaging System, a purpose-built 3D solution aimed at improving detection accuracy, especially in women with dense breast tissue. The release cites WHO and ACS data on global and U.S. breast cancer incidence to frame market demand.

Izotropic (OTCQB: IZOZF) released a CEO interview outlining near-term execution for its flagship IzoView dedicated breast CT platform.

Planned use of proceeds over the next 12–18 months includes funding for 3 IzoView devices, capital for a forthcoming U.S. FDA clinical study, one partner device in the U.K. while initiating CE‑mark activities, and two additional CE‑focused devices to build data and accelerate regulatory pathways. The CEO highlighted an exclusive CADx patent for breast CT and potential recurring revenues beyond device sales, and discussed regulatory, clinical, and market risks into 2026 with mitigation strategies.

Izotropic Corporation (OTCQB: IZOZF) announced placement in an editorial published by NetworkNewsWire on Oct 22, 2025, highlighting AI-enabled breast imaging and a projected $9 billion market for next‑gen 3D AI-imaging technologies.

The piece frames AI as a tool to improve early breast cancer detection and cites global statistics: 2.3 million diagnoses and ~670,000 deaths in 2022 (WHO) and 316,950 new invasive U.S. cases projected this year (ACS). The editorial spotlights Izotropic's IzoView Breast CT Imaging System, a dedicated 3D platform aimed at better detection for women with dense breast tissue.

Izotropic Corporation (OTCQB: IZOZF) was featured in CEO.CA's "Inside the Boardroom" interview on October 21, 2025, where CEO Robert Thast discussed the company's breast cancer technology and strategy.

The interview positions the technology as targeting 50% of women currently underserved by existing screening or diagnostic options and invites investors to view the full conversation via CEO.CA and YouTube. The piece also promotes CEO.CA as an investor social network with broad engagement and weekly executive interviews.

Izotropic (OTCQB: IZOZF) highlighted gaps in current breast imaging during Breast Cancer Awareness Month and positioned its IzoView Breast CT as a dedicated, true 3D adjunct for screening asymptomatic women with dense breasts. The company cited screening limits: ~20% cancers missed at mammography, 10–12% false negatives, and up to 50–60% of women experiencing a false positive within 10 years. Izotropic described IzoView as acquiring ~500 high-resolution images in ~10 seconds, reconstructing a true 3D volume, and targeting a device sales price of USD $500,000. The firm referenced market growth from USD $5.4B (2024) to $8.69B (2030, CAGR 8.25%) and research claims of breast CT offering markedly higher spatial resolution than MRI.

Izotropic (OTCQB: IZOZF) has published a new article on BreastCT.com highlighting the competitive advantages of its IzoView Breast CT Imaging System in AI-integrated breast imaging. The article emphasizes IzoView's purpose-built design for artificial intelligence integration, featuring a proprietary reconstruction algorithm and compression-free scanning capability that delivers high-quality 3D images in just 10 seconds.

The system, targeted at a USD $500K price point, addresses growing demand for advanced breast screening solutions, particularly for dense breast tissue. IzoView's architecture combines exclusive AI capabilities with scalable software features, positioning it as a future-ready platform in the evolving landscape of intelligent medical imaging.

Izotropic (OTCQB: IZOZF) has announced a groundbreaking advancement for its IzoView Breast CT Imaging System, introducing the first-ever patent-pending radiation dose personalization feature in breast CT systems. The system utilizes a radiation-free optical pre-scan technology to customize radiation doses based on individual breast size and composition.

The innovation comes as the global breast imaging market is projected to grow from $5.4 billion in 2024 to $8.69 billion by 2030. IzoView is advancing through the FDA's Pre-Market Approval process and plans a dual-path strategy for both U.S. and European market entry, leveraging data from its upcoming U.S. clinical study for CE Mark submission.

Izotropic Corporation (OTCQB: IZOZF) has launched a new FAQ webpage at www.izocorp.com/faq to enhance transparency and provide comprehensive information about its IzoView Breast CT Imaging System. The resource serves multiple stakeholders including investors, analysts, and healthcare professionals.

The FAQ page covers key topics such as IzoView's advantages over traditional imaging methods (mammography, tomosynthesis, ultrasound, and MRI), breast density's role in cancer detection, and the company's exclusive global commercialization rights for breast CT technology from UC Davis. The page is optimized for search engines and AI platforms to improve visibility across various channels.

Izotropic Corporation (OTCQB: IZOZF) has gained visibility in the expanding AI market through a sponsored editorial placement on MarketScreener.com. The article positions Izotropic as part of the next wave of AI innovation, focusing on specialized AI applications in healthcare.

The editorial highlights how AI is evolving beyond general applications to address specific industry challenges, particularly in healthcare, enterprise software, defense, and industrial automation. Izotropic's IzoView technology, which is approaching commercialization, is presented as a potential new standard in breast cancer imaging, combining disruptive technology with a strong IP portfolio.